肾细胞癌的关键生物标志物.pdf

1、Essential Biomarkers in RCCWenxin(Vincent)Xu,MDAssistant Professor of MedicineDana-Farber Cancer InstituteDisclosuresEXCLUSION ZONEResearch funding:DOD CDMRP KCRP AcademyASCO/Conquer Cancer FoundationDF/HCC Kidney Cancer SPOREOncohost(paid to institution)Merck(paid to institution)ArsenalBio(paid to

2、institution)Scientific advisory board/consulting:Jazz Exelixis Aveo Xencor Merck Eisai Celdara DecipheraBiomarkers in RCC are an unmet needDo I need adjuvant therapy?What is my recurrence risk?What is my kidney cancer risk?Pre-diagnosticLocalizedDo I need surgery?AdjuvantMetastaticDo I need systemic

3、 therapy?Is treatment working?Novel biomarkers have improved our understanding of RCC biologySaliby et al.,ASCO Educational Book 2024But using these biomarkers to individualize treatment remains elusiveTumoral PD-L1Immune cell PD-L1PD-1+TregsTertiary lymphoid structuresSomatic mutationsERV expressio

4、nGermline variantsRNA signaturesSingle cell RNA-seqCirculating proteins and cytokinesCell free DNACirculating tumor cellsTumor associated macrophagesClinicopathologic AI modelsNovel imagingMicrobiomeSaliby et al.,ASCO Educational Book 2024;Meylan et al.,Immunity 2022;Motzer et al.,Cancer Cell 2020;X

5、u et al.,Clin Cancer Res 2020;Smith et al.,J Clin Invest 2018;Panda et al.,JCI Insight 2018;Ficial et al.,Clin Cancer Res 2021;Denize et al.,Clin Cancer Res 2023;Rasmussen et al.,ASCO Educational Book 2022;Nuzzo et al.,Nat Med 2020;Shuch et al.,GU ASCO(LBA 602)2023;Rini et al.,Lancet Oncol 2015;Broo

6、ks et al.,Eur Urol 2014;Xu et al.,J Immunother Cancer 2023;Morrissey et al.,JAMA Onc 2015.TIM-3LAG-3KIM-1But using these biomarkers to individualize treatment remains elusiveTumoral PD-L1Immune cell PD-L1PD-1+TregsTertiary lymphoid structuresSomatic mutationsERV expressionGermline variantsRNA signat